CH505TF gp120

BIOLOGICAL2 trials

Sponsors

HIV Vaccine Trials Network

Conditions

HIV Infections

Phase 1

Evaluating Safety and Immune Response to the HIV-1 CH505 Transmitted/Founder gp120 Adjuvanted With GLA-SE in Healthy, HIV-exposed Uninfected Infants

CompletedNCT04607408

HIV Vaccine Trials NetworkHIV Infections

Start: 2020-11-10End: 2024-07-24Updated: 2026-01-29

Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of HIV-1 Chimp Adenovirus Vaccines Expressing Clade C gp140 & CH505TF gp120 Protein Boost in HIV-uninfected Adult.

CompletedNCT05182125

HIV Vaccine Trials NetworkHIV Infections

Start: 2021-11-25End: 2025-05-14Updated: 2025-12-24

Related Papers

Safety and implementation of phase I randomized GLA-SE–adjuvanted CH505TF gp120 HIV vaccine trial in newborns

Journal of Clinical Investigation2025-04-031 citations